CRISPR Therapeutics is the Switzerland-incorporated, Nasdaq-listed gene-editing parent behind Casgevy, the first commercially approved CRISPR/Cas9 therapy, and the print this quarter is the moment the commercial asset starts to throw off material economics. Second-quarter Casgevy revenue of $76M grew more than 150% year-over-year, as disclosed in the August business update. The FDA's recent pediatric label expansion opens an incremental addressable population of roughly 5,500 eligible patients, while the pipeline has widened with two new in vivo Phase 1 starts and an expanded zugo-cel autoimmune program.
The structural read underneath the print is the inflection from a research-and-development burn into a hybrid commercial-research P&L. Second-quarter net loss narrowed to $91.2M from $208.5M. The year-ago figure was inflated by an acquired research and development charge tied to the Sirius Therapeutics collaboration. Underlying R&D of $67.2M was down modestly year-over-year. Cash of $2.36B at quarter-end was lifted by approximately $585M of net convertible note proceeds, issued in March of this year.
The forward read across the next twelve months depends on whether each of these programs converts from clinical data point into a capital-allocation reality with sustained operating leverage. The question is whether Casgevy's growth curve, the autoimmune breadth of zugo-cel, and the in vivo liver editing platform can each produce that conversion, given the existing $2.36B cash position and the long-runway math.